• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PfRH5疫苗:从实验室到药瓶

PfRH5 vaccine; from the bench to the vial.

作者信息

Ilani Philip, Nyarko Prince B, Camara Abdouramane, Amenga-Etego Lucas N, Aniweh Yaw

机构信息

West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of Ghana, Legon, Accra, Ghana.

Laboratory of Pathogens and Host Immunity (LPHI), CNRS, University of Montpellier, Montpellier, France.

出版信息

NPJ Vaccines. 2025 Apr 24;10(1):82. doi: 10.1038/s41541-025-01137-6.

DOI:10.1038/s41541-025-01137-6
PMID:40274841
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12022022/
Abstract

The search for potent malaria vaccine candidate has seen several twists and turns. Here, we provide a perspective on the current state of PfRH5-based malaria vaccine development, the progress, existing challenges, and future research directions. We discuss the clinical trials in endemic regions, immune correlates of protection, prospects of integrating PfRH5 into multi-antigen vaccine strategies and considerations on the onward development/deployment of PfRH5 vaccine from the laboratory to endemic communities.

摘要

寻找有效的疟疾疫苗候选物历经了诸多波折。在此,我们对基于疟原虫红细胞结合蛋白5(PfRH5)的疟疾疫苗研发现状、进展、现存挑战及未来研究方向进行了展望。我们讨论了在疟疾流行地区开展的临床试验、保护的免疫相关因素、将PfRH5整合到多抗原疫苗策略中的前景,以及关于PfRH5疫苗从实验室到流行社区的进一步研发/部署的考量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05d7/12022022/4f44ee488b47/41541_2025_1137_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05d7/12022022/6aed80c11449/41541_2025_1137_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05d7/12022022/4f44ee488b47/41541_2025_1137_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05d7/12022022/6aed80c11449/41541_2025_1137_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05d7/12022022/4f44ee488b47/41541_2025_1137_Fig2_HTML.jpg

相似文献

1
PfRH5 vaccine; from the bench to the vial.PfRH5疫苗:从实验室到药瓶
NPJ Vaccines. 2025 Apr 24;10(1):82. doi: 10.1038/s41541-025-01137-6.
2
Estimation of PfRh5-based vaccine efficacy in asymptomatic patients from high-endemic areas of Tanzania using genetic and antigenicity variation screening.利用基因和抗原性变异筛查评估坦桑尼亚高流行地区无症状患者中基于PfRh5的疫苗效力。
Front Immunol. 2024 Nov 18;15:1495513. doi: 10.3389/fimmu.2024.1495513. eCollection 2024.
3
Structure-guided insights into potential function of novel genetic variants in the malaria vaccine candidate PfRh5.结构导向洞察疟疾疫苗候选蛋白 PfRh5 新型遗传变异的潜在功能
Sci Rep. 2022 Nov 12;12(1):19403. doi: 10.1038/s41598-022-23929-9.
4
Genetic polymorphisms in malaria vaccine candidate Plasmodium falciparum reticulocyte-binding protein homologue-5 among populations in Lagos, Nigeria.尼日利亚拉各斯人群疟原虫红细胞结合蛋白同源物 5 候选疫苗中的遗传多态性。
Malar J. 2020 Jan 6;19(1):6. doi: 10.1186/s12936-019-3096-0.
5
Genetic diversity of Plasmodium falciparum reticulocyte binding protein homologue-5, which is a potential malaria vaccine candidate: baseline data from areas of varying malaria endemicity in Mainland Tanzania.恶性疟原虫网织红细胞结合蛋白同源物5的遗传多样性,该蛋白是一种潜在的疟疾疫苗候选物:坦桑尼亚大陆不同疟疾流行程度地区的基线数据
Malar J. 2025 Jan 27;24(1):29. doi: 10.1186/s12936-025-05269-x.
6
A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein.一种基于恶性疟原虫RH5蛋白表位的疟疾候选疫苗。
Malar J. 2014 Aug 18;13:326. doi: 10.1186/1475-2875-13-326.
7
APC-Targeted DNA Vaccination Against Reticulocyte-Binding Protein Homolog 5 Induces -Specific Neutralizing Antibodies and T Cell Responses.针对网织红细胞结合蛋白同源物5的APC靶向DNA疫苗接种可诱导特异性中和抗体和T细胞反应。
Front Immunol. 2021 Oct 18;12:720550. doi: 10.3389/fimmu.2021.720550. eCollection 2021.
8
High genetic and haplotype diversity in vaccine candidate but not among malaria-infected children in Ibadan, Nigeria.在尼日利亚伊巴丹,候选疫苗具有高遗传和单倍型多样性,但疟疾感染儿童中没有。
PeerJ. 2023 Dec 11;11:e16519. doi: 10.7717/peerj.16519. eCollection 2023.
9
Naturally acquired antibodies specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria.天然产生的针对恶性疟原虫红细胞结合蛋白同源物 5 的抗体可抑制寄生虫生长,并可预测对疟疾的保护作用。
J Infect Dis. 2014 Mar 1;209(5):789-98. doi: 10.1093/infdis/jit553. Epub 2013 Oct 16.
10
Bacterially expressed full-length recombinant Plasmodium falciparum RH5 protein binds erythrocytes and elicits potent strain-transcending parasite-neutralizing antibodies.细菌表达全长重组恶性疟原虫 RH5 蛋白与红细胞结合,并引发强效的跨株寄生虫中和抗体。
Infect Immun. 2014 Jan;82(1):152-64. doi: 10.1128/IAI.00970-13. Epub 2013 Oct 14.

引用本文的文献

1
Emerging Molecular Mechanisms in Malaria Pathogenesis and Novel Therapeutic Approaches: A Focus on Malaria.疟疾发病机制中的新兴分子机制与新型治疗方法:聚焦疟疾
Biomolecules. 2025 Jul 17;15(7):1038. doi: 10.3390/biom15071038.

本文引用的文献

1
Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children.血液期疟疾疫苗RH5.1/Matrix-M在布基纳法索的安全性和有效性:儿童双盲、随机、对照2b期试验的中期结果
Lancet Infect Dis. 2025 May;25(5):495-506. doi: 10.1016/S1473-3099(24)00752-7. Epub 2024 Dec 10.
2
Red blood cell signaling is functionally conserved in invasion.红细胞信号传导在侵袭过程中功能保守。
iScience. 2024 Sep 26;27(10):111052. doi: 10.1016/j.isci.2024.111052. eCollection 2024 Oct 18.
3
Estimation of PfRh5-based vaccine efficacy in asymptomatic patients from high-endemic areas of Tanzania using genetic and antigenicity variation screening.
利用基因和抗原性变异筛查评估坦桑尼亚高流行地区无症状患者中基于PfRh5的疫苗效力。
Front Immunol. 2024 Nov 18;15:1495513. doi: 10.3389/fimmu.2024.1495513. eCollection 2024.
4
Vaccine-induced human monoclonal antibodies to PfRH5 show broadly neutralizing activity against P. falciparum clinical isolates.疫苗诱导产生的针对恶性疟原虫红细胞结合抗原5(PfRH5)的人源单克隆抗体对恶性疟原虫临床分离株具有广泛的中和活性。
NPJ Vaccines. 2024 Oct 24;9(1):198. doi: 10.1038/s41541-024-00986-x.
5
RH5: rationally-designed malaria vaccine antigen improving efficacy.RH5:经过理性设计的疟疾疫苗抗原,提高了疗效。
Trends Parasitol. 2024 Oct;40(10):870-872. doi: 10.1016/j.pt.2024.09.001. Epub 2024 Sep 13.
6
Rational structure-guided design of a blood stage malaria vaccine immunogen presenting a single epitope from PfRH5.理性结构导向设计的血期疟原虫疫苗免疫原,呈现 PfRH5 的单个表位。
EMBO Mol Med. 2024 Oct;16(10):2539-2559. doi: 10.1038/s44321-024-00123-0. Epub 2024 Sep 2.
7
Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5.天然疟疾感染会引发针对血期抗原 RH5 的罕见但强效的中和抗体。
Cell. 2024 Sep 5;187(18):4981-4995.e14. doi: 10.1016/j.cell.2024.06.037. Epub 2024 Jul 25.
8
Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotype.分析疟疾蛋白 RH5 的多样化抗原表位,鉴定出一种有效的疫苗诱导的人类公共抗体克隆型。
Cell. 2024 Sep 5;187(18):4964-4980.e21. doi: 10.1016/j.cell.2024.06.015. Epub 2024 Jul 25.
9
Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies.一种能诱导产生改良抗疟抗体的稳定化RH5病毒样颗粒疫苗的临床前开发。
Cell Rep Med. 2024 Jul 16;5(7):101654. doi: 10.1016/j.xcrm.2024.101654.
10
Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial.健康坦桑尼亚成年人及儿童中血期疟疾候选疫苗RH5.1/Matrix-M;一项开放标签、非随机、人体首例、单中心1b期试验。
Lancet Infect Dis. 2024 Oct;24(10):1105-1117. doi: 10.1016/S1473-3099(24)00312-8. Epub 2024 Jun 13.